May Measurement Month 2017: an analysis of blood pressure screening in the Philippines-South-East Asia and Australasia.


Journal

European heart journal supplements : journal of the European Society of Cardiology
ISSN: 1520-765X
Titre abrégé: Eur Heart J Suppl
Pays: England
ID NLM: 100886647

Informations de publication

Date de publication:
Apr 2019
Historique:
entrez: 3 5 2019
pubmed: 3 5 2019
medline: 3 5 2019
Statut: ppublish

Résumé

Cardiovascular diseases remain the Philippines' leading cause of mortality, with hypertension as a prevalent contributory risk factor. We took part in May Measurement Month 2017 (MMM17), a global initiative to raise awareness of high blood pressure (BP) and to serve as a temporary solution to the lack of screening programs worldwide. Following the standard MMM protocol, data for 271 604 screened individuals were submitted from the Philippines. After multiple imputation, 91 994 (34.3%) were hypertensive; 28 662 out of 205 158 participants (14.0%) not receiving treatment had hypertension; and of the 60 370 receiving treatment, 25 144 (41.6%) had uncontrolled BP. Blood pressures were significantly higher in the overweight and obese, current smokers, in participants receiving antihypertensive medication, those with previous myocardial infarction or stroke. The BP measurements were relatively lower when taken on the left arm, and in pregnant women. A slightly higher systolic BP was noted in participants who reported no alcohol intake. Blood pressures recorded during the weekends were highest, and the lowest readings were obtained on Tuesdays. MMM17 was the largest BP screening campaign conducted in the Philippines. Opportunistic BP screening, harnessing volunteers, are a cost-effective public health measure to improve awareness and treatment rates of raised BP. These may help provide additional information that can guide medical practitioners and health officials in drafting preventive and therapeutic measures to improve control rates and long-term outcomes of hypertensive individuals in the population.

Identifiants

pubmed: 31043890
doi: 10.1093/eurheartj/suz066
pii: suz066
pmc: PMC6479502
doi:

Types de publication

Journal Article

Langues

eng

Pagination

D92-D96

Références

Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Lancet. 2017 Apr 29;389(10080):1678-1680
pubmed: 28463128
Lancet Glob Health. 2018 Jul;6(7):e736-e743
pubmed: 29778399
BMC Public Health. 2017 Oct 10;17(1):797
pubmed: 29017534
JAMA. 2017 Jan 10;317(2):165-182
pubmed: 28097354

Auteurs

Rafael R Castillo (RR)

Manila Doctor's Hospital, College of Medicine Adventist University of the Philippines, Philippines.

Alberto A Atilano (AA)

Section of Cardiology, University of Santo Tomas, Philippines.

Deborah Ignacia David-Ona (DI)

Section of Hypertension, University of the Philippines-Philippine General Hospital, St. Luke's Medical Center, Global City, Philippines.

Carmela Napiza-Granada (C)

Disease Prevention and Control Bureau, Department of Health, Philippines.

Ma Rosario Cruz-Sevilla (MR)

Asian Hospital and Medical Center and LRI-Therapharma, Philippines.

Hazel Torreblanca (H)

Disease Prevention and Control Bureau, Department of Health, Philippines.

Robert Castro (R)

HealthFirst Medical Clinics, Philippines.

Lynn A Gomez (LA)

Section of Nephrology, University of the Philippines-Philippine General Hospital, Philippines.

Leilani B Mercado-Asis (LB)

Section of Endocrinology and Metabolism, Faculty of Medicine and Surgery, University of Santo Tomas, Philippines.

Dolores D Bonzon (DD)

Physiology Section, University of the Philippines College of Medicine, Philippines.

Alejandro F Diaz (AF)

Section of Neuro-Psychiatry, University of Santo Tomas, Philippines.

Gilbert C Vilela (GC)

Department of Education, Philippine Heart Center, Philippines.

Carlos L Chua (CL)

Section of Neurology, Manila Doctor's Hospital, Philippines.

Jorge A Sison (JA)

Section of Cardiology, Medical Center Manila, Philippines.

Thomas Beaney (T)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Xin Xia (X)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Neil R Poulter (NR)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Classifications MeSH